Assessment of the clinical significance of production of extended-spectrum β-lactamases (ESBL) by enterobacteriaceae

Infection

Volumn 34, Issue 2, 2006, Pages 66-74

  Henshke Bar Meir, R ^a   Yinnon, A M ^a   Rudensky, B ^a   Attias, D ^a   Schlesinger, Y ^a   Raveh, D ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIBIOTIC RESISTANCE; APACHE; ARTICLE; BLOOD CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; ENTEROBACTERIACEAE; FEMALE; HOSPITAL INFECTION; HUMAN; INDWELLING CATHETER; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NURSING HOME; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; COHORT STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; ISRAEL; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33646752391     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-006-4114-z     Document Type: Article

References (30)

1. Gold HS, Moellering RC: Antimicrobial drug resistance. N Engl J Med 1996; 335: 1445-1453.
2. Medeiros AA: Nosocomial outbreaks of multiresistant bacteria: extended-spectrum beta-lactamases have arrived in North America. Ann Intern Med 1993; 119: 428-429.
3. Livermore DM: β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
4. Jacoby GA: Extended-spectrum β-lactamases and other enzymes providing resistance to oxymino-β-lactams. Infect Dis Clin North Am 1997; 11: 875-887.
5. National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing. In: 11th informational supplement. NCCLS document M100-S11. NCCLS, Wayne, PA, 2001.
6. Chopra I, Hodgson J, Metcalf B, Poste G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997; 41: 497-503.
7. Cunha BA: Antibiotic resistance: myths, truths and a rational formulary approach. Formulary 1999; 34: 664-682.
8. Tallis E, Rudensky B, Attias D, Yinnon AM: In vitro susceptibility of diverse groups of Enterobacteriaceae and Staphylococcus aureus to cefepime and comparable antimicrobials. Diagn Microbiol Infect Dis 1999; 35: 121-126.
9. Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rudensky B: A six year survey of Klebsiella bacteremia: community versus nosocomial infection. Quart J Med 1996; 89: 933-941.
10. Yinnon AM, Schlesinger Y, Gabbay D, Rudensky B: Analysis of five years of bacteremias: importance of stratification of microbial susceptibilities by source of patients. J Infect 1997; 35: 17-23.
11. Raveh D, Rudensky B, Schlesinger Y, Benenson S, Yinnon AM: Susceptibility trends in bacteraemias: analyses of 7544 patient-unique bacteraemic episodes spanning 11 years (1990-2000). J Hosp Infect 2003; 55: 196-203.
12. Quale JM, Landman D, Bradford PA, Visalli M, Ravishankar J, Flores C, Mayorga D, Vangala K, Adedeji A: Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002; 35: 834-841.
13. Emery CL, Weymouth LA: Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35: 2061-2067.
14. Thomson KS, Smith Moland E: Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrobial Agents Chemother 2001; 45: 3548-3554.
15. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, Eliopoulos GM: Efficacy of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41: 1053-1057.
16. Brun-Buisson CP, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J: Transferable enzymatic resistance to third generation cephalosporins during nosocomial outbreak of multiresistant K. pneumoniae. Lancet 1987; ii: 302-306.
17. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO: Extended-spectrum β-lactamase-producing E.coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-1171.
18. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
19. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, Riesenberg K, Schlaeffer F: Clinical significance and impact on mortality of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33: 188-193.
20. Ho P-L, Chan W-M, Tsang KWT, Wong SSY, Young K: Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-573.
21. Kim B-N, Woo J-H, Kim M-N, Ryu J, Kim YS: Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia. J Hosp Infect 2002; 52: 99-106.
22. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goosens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA Rice LB, Wagener MM, McCormack JG, Yu VL: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-37.
23. Rice LB, Eckstein EC, DeVente J, Shlaes DM: Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118-124.
24. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH: Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-458.
25. Navon-Venezia S, Hammer-Munz O, Schwartz D, Turner D, Kuzmenko B, Carmeli Y: Occurrence and phenotypic characteristics of extended-spectrum β-lactamases among members of the family Enterobacteriaceae at the Tel Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol 2003; 41: 155-158.
26. Wenzel RP, Edmond MB: The impact of hospital-acquired infections. Emerg Infect Dis 2001; 7: 174-177.
27. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E: Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended spectrum β-lactamase-producing Enterobacteriaceae. Variability by site of infection. Arch Intern Med 2005; 165: 1375-1380.
28. Kim BN, Woo JH, Ryu J, Kim YS: Resistance to extended-spectrum cephalosporins and mortality in patients with Citrobacter freundii bacteremia. Infection 2003; 31: 202-207.
29. Toubes E, Singh K, Yin D, Glick N, Russell L, Mohapatra S, Saghal N, Weinstein RA, Trenholme G: Risk factors for antibiotic resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Infect Dis 2003; 36: 724-730.
30. Ambrose PG, Bhavnani SM, Jones RN: Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003; 47: 1643-1646.